"India is fully Trade Related Aspects of Intellectual Property Rights (TRIPS) compliant and India is not going to accept any investigations or anything which is TRIPS plus," Commerce and Industry Minister Anand Sharma told reporters here.
"So we are very clear as to what we have to do. We would take any measure as required to protect our producers, our farmers and that is what we have communication with all firmness," he added.
However, the US has said that they would do a 'out-of-cycle' review of India's IPR regime.
"We are very firm and consistent on (Special) 301 issue and finally the US saw sense when it comes to Indian IPR regime," the minister said.
Also Read
The Obama administration had been strongly critical of India's investment climate and IPR laws, especially in the pharmaceutical and solar sectors.
Swiss pharma major Novartis lost the legal battle to get its blood cancer drug Glivec patented in India and restrain domestic companies from manufacturing generic versions.
India has always maintained that its IPR regime is fully compliant with WTO norms and it would drag the US to the global trade body if any adverse unilateral step is taken against the country in IPR-related matters.
Replying a question about FDI in multi-brand retail trading issue, Sharma said that the policy was announced after wider consultations with all the stakeholders.
"Giving an option does not mean a revolving door. FDI policy have to have a predictability and stability," he said.
Rajasthan and Delhi withdrew approval for FDI in multi-brand retail following a change of government after the assembly elections held in November-December last year. The Congress lost to the Bharatiya Janata Party in Rajasthan and to the Aam Aadmi Party in Delhi.